Cargando…

Pathophysiology and Current Drug Treatments for Post-Stroke Depression: A Review

Post-stroke depression (PSD) is a biopsychosocial disorder that affects individuals who have suffered a stroke at any point. PSD has a 20 to 60 percent reported prevalence among stroke survivors. Its effects are usually adverse, can lead to disability, and may increase mortality if not managed or tr...

Descripción completa

Detalles Bibliográficos
Autores principales: Frank, Dmitry, Gruenbaum, Benjamin F., Zlotnik, Alexander, Semyonov, Michael, Frenkel, Amit, Boyko, Matthew
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9738261/
https://www.ncbi.nlm.nih.gov/pubmed/36499434
http://dx.doi.org/10.3390/ijms232315114
_version_ 1784847495424114688
author Frank, Dmitry
Gruenbaum, Benjamin F.
Zlotnik, Alexander
Semyonov, Michael
Frenkel, Amit
Boyko, Matthew
author_facet Frank, Dmitry
Gruenbaum, Benjamin F.
Zlotnik, Alexander
Semyonov, Michael
Frenkel, Amit
Boyko, Matthew
author_sort Frank, Dmitry
collection PubMed
description Post-stroke depression (PSD) is a biopsychosocial disorder that affects individuals who have suffered a stroke at any point. PSD has a 20 to 60 percent reported prevalence among stroke survivors. Its effects are usually adverse, can lead to disability, and may increase mortality if not managed or treated early. PSD is linked to several other medical conditions, including anxiety, hyper-locomotor activity, and poor functional recovery. Despite significant awareness of its adverse impacts, understanding the pathogenesis of PSD has proved challenging. The exact pathophysiology of PSD is unknown, yet its complexity has been definitively shown, involving mechanisms such as dysfunction of monoamine, the glutamatergic systems, the gut-brain axis, and neuroinflammation. The current effectiveness of PSD treatment is about 30–40 percent of all cases. In this review, we examined different pathophysiological mechanisms and current pharmacological and non-pharmacological approaches for the treatment of PSD.
format Online
Article
Text
id pubmed-9738261
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-97382612022-12-11 Pathophysiology and Current Drug Treatments for Post-Stroke Depression: A Review Frank, Dmitry Gruenbaum, Benjamin F. Zlotnik, Alexander Semyonov, Michael Frenkel, Amit Boyko, Matthew Int J Mol Sci Review Post-stroke depression (PSD) is a biopsychosocial disorder that affects individuals who have suffered a stroke at any point. PSD has a 20 to 60 percent reported prevalence among stroke survivors. Its effects are usually adverse, can lead to disability, and may increase mortality if not managed or treated early. PSD is linked to several other medical conditions, including anxiety, hyper-locomotor activity, and poor functional recovery. Despite significant awareness of its adverse impacts, understanding the pathogenesis of PSD has proved challenging. The exact pathophysiology of PSD is unknown, yet its complexity has been definitively shown, involving mechanisms such as dysfunction of monoamine, the glutamatergic systems, the gut-brain axis, and neuroinflammation. The current effectiveness of PSD treatment is about 30–40 percent of all cases. In this review, we examined different pathophysiological mechanisms and current pharmacological and non-pharmacological approaches for the treatment of PSD. MDPI 2022-12-01 /pmc/articles/PMC9738261/ /pubmed/36499434 http://dx.doi.org/10.3390/ijms232315114 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Frank, Dmitry
Gruenbaum, Benjamin F.
Zlotnik, Alexander
Semyonov, Michael
Frenkel, Amit
Boyko, Matthew
Pathophysiology and Current Drug Treatments for Post-Stroke Depression: A Review
title Pathophysiology and Current Drug Treatments for Post-Stroke Depression: A Review
title_full Pathophysiology and Current Drug Treatments for Post-Stroke Depression: A Review
title_fullStr Pathophysiology and Current Drug Treatments for Post-Stroke Depression: A Review
title_full_unstemmed Pathophysiology and Current Drug Treatments for Post-Stroke Depression: A Review
title_short Pathophysiology and Current Drug Treatments for Post-Stroke Depression: A Review
title_sort pathophysiology and current drug treatments for post-stroke depression: a review
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9738261/
https://www.ncbi.nlm.nih.gov/pubmed/36499434
http://dx.doi.org/10.3390/ijms232315114
work_keys_str_mv AT frankdmitry pathophysiologyandcurrentdrugtreatmentsforpoststrokedepressionareview
AT gruenbaumbenjaminf pathophysiologyandcurrentdrugtreatmentsforpoststrokedepressionareview
AT zlotnikalexander pathophysiologyandcurrentdrugtreatmentsforpoststrokedepressionareview
AT semyonovmichael pathophysiologyandcurrentdrugtreatmentsforpoststrokedepressionareview
AT frenkelamit pathophysiologyandcurrentdrugtreatmentsforpoststrokedepressionareview
AT boykomatthew pathophysiologyandcurrentdrugtreatmentsforpoststrokedepressionareview